157 related articles for article (PubMed ID: 28132761)
1. Restenosis After Everolimus-eluting Vascular Scaffolding. Angiographic and Optical Coherence Tomography Characterization.
Chavarría J; Suárez de Lezo J; Ojeda S; Pan M; Segura J; Mazuelos F; Espejo S; López J; Romero M; Suárez de Lezo J
Rev Esp Cardiol (Engl Ed); 2017 Jul; 70(7):543-550. PubMed ID: 28132761
[TBL] [Abstract][Full Text] [Related]
2. Optimal threshold of postintervention minimum stent area to predict in-stent restenosis in small coronary arteries: An optical coherence tomography analysis.
Matsuo Y; Kubo T; Aoki H; Satogami K; Ino Y; Kitabata H; Taruya A; Nishiguchi T; Teraguchi I; Shimamura K; Shiono Y; Orii M; Yamano T; Tanimoto T; Yamaguchi T; Hirata K; Tanaka A; Akasaka T
Catheter Cardiovasc Interv; 2016 Jan; 87(1):E9-E14. PubMed ID: 26268150
[TBL] [Abstract][Full Text] [Related]
3. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
[TBL] [Abstract][Full Text] [Related]
4. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM
Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436
[TBL] [Abstract][Full Text] [Related]
6. Association of morphologic characteristics on optical coherence tomography and angiographic progression patterns of late restenosis after drug-eluting stent implantation.
Yamaguchi H; Arikawa R; Takaoka J; Miyamura A; Atsuchi N; Ninomiya T; Atsuchi Y; Ohishi M; Terashima M; Kaneda H
Cardiovasc Revasc Med; 2015; 16(1):32-5. PubMed ID: 25617940
[TBL] [Abstract][Full Text] [Related]
7. Optical coherence tomography-guided versus angiography-guided implantation of everolimus-eluting bioresorbable vascular scaffolds: Comparison of coverage, apposition and clinical outcome. The ALSTER-OCT ABSORB registry.
Heeger CH; Schedifka AS; Meincke F; Spangenberg T; Wienemann H; Kreidel F; Kuck KH; Ghanem A; Bergmann MW
Cardiol J; 2018; 25(4):459-469. PubMed ID: 29512092
[TBL] [Abstract][Full Text] [Related]
8. In-Stent Restenosis with "Inflammatory" Neointima Following Everolimus-Eluting Stent Implantation.
Tsuji Y; Koide M; Katsura K; Fujita H; Ishibashi-Ueda H; Otsuka F
Int Heart J; 2018 Sep; 59(5):1142-1145. PubMed ID: 30012926
[TBL] [Abstract][Full Text] [Related]
9. Early (before 6 months), late (6-12 months) and very late (after 12 months) angiographic scaffold restenosis in the ABSORB Cohort B trial.
Nakatani S; Onuma Y; Ishibashi Y; Muramatsu T; Iqbal J; Zhang YJ; van Geuns RJ; Ormiston JA; Serruys PW
EuroIntervention; 2015 Mar; 10(11):1288-98. PubMed ID: 24572936
[TBL] [Abstract][Full Text] [Related]
10. Quantitative optical coherence tomography analysis for late in-stent restenotic lesions.
Fu Q; Suzuki N; Kozuma K; Miyagawa M; Nomura T; Kawashima H; Shiratori Y; Ishikawa S; Kyono H; Isshiki T
Int Heart J; 2015; 56(1):13-7. PubMed ID: 25503658
[TBL] [Abstract][Full Text] [Related]
11. Coronary Artery Aneurysm After Bioresorbable Scaffold Implantation in a Woman With an Acute Coronary Syndrome.
Cereda AF; Canova PA; Oreglia JA; Soriano FS
J Invasive Cardiol; 2017 Jul; 29(7):E77-E78. PubMed ID: 28667808
[TBL] [Abstract][Full Text] [Related]
12. An Impressive Case of "Honeycomb" In-Stent Restenosis.
Lorenzoni G; Merella P; Viola G; Marziliano N; Casu G
J Invasive Cardiol; 2018 Sep; 30(9):E99. PubMed ID: 30158330
[TBL] [Abstract][Full Text] [Related]
13. Comparison of in-stent neoatherosclerosis and tissue characteristics between early and late in-stent restenosis in second-generation drug-eluting stents: an optical coherence tomography study.
Sabbah M; Kadota K; El-Eraky A; Kamal HM; Abdellah AT; El Hawary A
Int J Cardiovasc Imaging; 2017 Oct; 33(10):1463-1472. PubMed ID: 28444549
[TBL] [Abstract][Full Text] [Related]
14. The AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusion (ACE-CTO) Study.
Kotsia A; Navara R; Michael TT; Sherbet DP; Roesle M; Christopoulos G; Rangan BV; Haagen D; Garcia S; Maniu C; Pershad A; Abdullah SM; Hastings JL; Kumbhani DJ; Luna M; Addo T; Banerjee S; Brilakis ES
J Invasive Cardiol; 2015 Sep; 27(9):393-400. PubMed ID: 26332874
[TBL] [Abstract][Full Text] [Related]
15. Bioresorbable vascular scaffolds in coronary chronic total occlusions revascularization: safety assessment related to struts coverage and apposition in 6-month OCT follow-up.
Abellas-Sequeiros RA; Ocaranza-Sanchez R; Trillo-Nouche R; Gonzalez-Juanatey C; Gonzalez-Juanatey JR
Heart Vessels; 2017 Sep; 32(9):1077-1084. PubMed ID: 28432385
[TBL] [Abstract][Full Text] [Related]
16. Initial and late efficacy of everolimus-eluting stents for small and non-small coronary lesions from evaluating delayed late loss study.
Tama N; Uzui H; Horita Y; Namura M; Tada H
Heart Vessels; 2017 Dec; 32(12):1415-1423. PubMed ID: 28687988
[TBL] [Abstract][Full Text] [Related]
17. Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial.
Kallinikou Z; Arroyo D; Togni M; Lehman S; Corpataux N; Cook M; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Puricel SG; Cook S
Swiss Med Wkly; 2016; 146():w14274. PubMed ID: 26766027
[TBL] [Abstract][Full Text] [Related]
18. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up.
Serruys PW; Ormiston J; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Chevalier B; Smits P; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Wasungu L; Ediebah D; Veldhof S; Onuma Y
J Am Coll Cardiol; 2016 Feb; 67(7):766-76. PubMed ID: 26892411
[TBL] [Abstract][Full Text] [Related]
19. Post-dilatation after implantation of bioresorbable everolimus- and novolimus-eluting scaffolds: an observational optical coherence tomography study of acute mechanical effects.
Blachutzik F; Boeder N; Wiebe J; Mattesini A; Dörr O; Most A; Bauer T; Röther J; Tröbs M; Schlundt C; Achenbach S; Hamm CW; Nef HM
Clin Res Cardiol; 2017 Apr; 106(4):271-279. PubMed ID: 27757522
[TBL] [Abstract][Full Text] [Related]
20. Vascular response and healing profile of everolimus-eluting bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: A one-year optical coherence tomography analysis from the GHOST-CTO registry.
La Manna A; Miccichè E; D'Agosta G; Tensol Rodrigues Pereira G; Attizzani GF; Capranzano P; Capodanno D; Tamburino C
Int J Cardiol; 2018 Feb; 253():45-49. PubMed ID: 29137819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
